Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 132

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 132
---
 sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

| 74 |

Cash Flows for the Years Ended December 31, 2024 and 2023

The following table shows
a summary of our cash flows for the years ended December 31, 2024 and 2023.

|                                           |     | Fiscal Years Ended December 31, |       2024 |   |     |   |     2023 |   |
|:------------------------------------------|:----|:--------------------------------|-----------:|:--|:----|:--|---------:|:--|
| Net cash used in operating activities     |     | $                               | (3,911,004 | ) |     | $ | (480,953 | ) |
| Net cash used in investing activities     |     |                                 |          - |   |     |   |        - |   |
| Net cash provided by financing activities |     | $                               |  7,652,036 |   |     | $ |  445,000 |   |
| Net increase (decrease) in cash           |     | $                               |  3,741,032 |   |     | $ |  (35,953 | ) |
| Cash - beginning of the period            |     | $                               |            |   |     | $ |          |   |
| Cash - end of the period                  |     | $                               |  3,769,510 |   |     | $ |   28,478 |   |

Net Cash Used in Operating Activities:

Net cash used in operating
activities during the year ended December 31, 2024 increased $3,430,051 from December 31, 2023 mainly attributable to an increase of $2,300,000
in prepaid contracts due to stock issuances associated with Asian business development service agreements, an increase of $118,796 in
other current assets, a decrease of $2,187,051 in accrued compensation, a decrease of $314,412 in accounts payable and accrued expenses,
a decrease of $1,517,085 in changes associated with debt (amortization of debt discounts, loss on extinguishment of debt, gain/loss on
change in fair value of derivative liabilities, and increase in accrued interest), an increase in